Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Foghorn Therapeutics (FHTX) over the last 2 years, with Jun 2025 value amounting to -$8,000.

  • Foghorn Therapeutics' Gains from Investment Securities fell 101.13% to -$8,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 50.06%. This contributed to the annual value of $860,000 for FY2024, which is 75.78% down from last year.
  • Foghorn Therapeutics' Gains from Investment Securities amounted to -$8,000 in Q2 2025, which was down 100.66% from $1.2 million recorded in Q1 2025.
  • Over the past 5 years, Foghorn Therapeutics' Gains from Investment Securities peaked at $1.7 million during Q2 2023, and registered a low of -$8,000 during Q2 2025.
  • Its 3-year average for Gains from Investment Securities is $623,444, with a median of $705,000 in 2024.
  • Data for Foghorn Therapeutics' Gains from Investment Securities shows a peak YoY increase of 2,365.31% (in 2025) and a maximum YoY decrease of 101.13% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Foghorn Therapeutics' Gains from Investment Securities stood at $865,000 in 2023, then plummeted by 94.57% to $47,000 in 2024, then crashed by 101.13% to -$8,000 in 2025.
  • Its Gains from Investment Securities was -$8,000 in Q2 2025, compared to $1.2 million in Q1 2025 and $47,000 in Q4 2024.